Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Thyroid cancer is the commonest endocrine malignancy, and drugs that target protein kinases offer a new approach in combating this and other malignancies. This review describes the various kinase targets in thyroid cancers, and details the inhibitors of the kinases RET and BRAF that are now in clinical trials.